Acme United Q2 2026 Results Show Margin Recovery And Institutional Accumulation

• Acme United reported Q2 2026 net sales of $62.7 million, a 16% year-over-year increase driven by the recent acquisition of MyMedic and core business recovery.
• Wall Street analysts maintain a Strong Buy consensus with an average price target of $64.26, implying a 3.91% upside from current trading levels.
• Institutional investors, including Bank of New York Mellon, have increased their stakes, signaling confidence despite concurrent insider selling activity.
• Management anticipates continued margin expansion as lower-cost inventory replaces higher-tariff stock, though elevated SG&A expenses remain a key risk.

Acme United Corporation delivered a robust financial performance for the second quarter of 2026, underscoring the successful integration of its recent strategic acquisitions. The company reported net sales of $62.7 million, representing a significant 16% increase from the $54 million recorded in the prior year period . This growth trajectory was primarily fueled by the acquisition of MyMedic, which closed in January 2026 and contributed $4.3 million in sales during the quarter .

Net income rose by 6% to $5.1 million, or $1.22 per diluted share, beating the $0.81 forecast . The earnings beat contributed to an 11.92% share surge, pushing the stock near its 52-week highs . Excluding the impact of the MyMedic acquisition, organic sales grew by 8%, supported by a 10% increase in U.S. first aid and medical products and an 8% rise in Westcott Cutting Tools sales . This dual engine of organic growth and acquisition-driven expansion highlights the company's diversified market presence.

How Did The MyMedic Acquisition Impact Profitability?

The acquisition of MyMedic has played a pivotal role in reshaping Acme United's profitability structure. Gross margins expanded to 42.6% from 41.0% in the prior year, largely attributable to the high-margin direct-to-consumer MyMedic business . However, the company noted that MyMedic currently operates at break-even due to high advertising costs, which are expected to decrease as the business scales .

Management highlighted that without MyMedic, U.S. gross margins would have declined by approximately 100 basis points due to the pass-through of high tariff costs capitalized in inventory . These headwinds are expected to diminish as lower-cost inventory replaces higher-tariff stock and tariff rates decline . The company is transitioning from a purely direct-to-consumer model to retail distribution, leveraging Acme’s existing mass-market relationships to boost long-term profitability .

Strategically, Acme is integrating MyMedic with a focus on expanding its distribution beyond direct-to-consumer into mass retail channels . The company expects strong Q4 profitability driven by seasonal demand and holiday spending . This strategic pivot is expected to enhance operational leverage and improve the overall margin profile of the acquired entity.

What Is The Market And Analyst Sentiment?

Wall Street analysts maintain a Strong Buy consensus for Acme United based on inputs from six analysts . The mean price target stands at $64.26, representing a 3.91% potential upside from the current price of $61.84 . The price target range spans from a low of $58.58 to a high of $71.40 . Notably, analyst sentiment has shifted positively, with the average price target revised upward by 26% in the last three months .

Upcoming earnings are scheduled for October 19, 2026, for the third quarter . Consensus estimates project an EPS of $0.69 and revenue of $56.95 million, reflecting a 16.08% quarter-over-quarter revenue growth . While revenue estimates have remained stable, EPS estimates have seen a slight downward revision of 6.45% over the past three months . Long-term forward forecasts suggest a 7.43% Compound Annual Growth Rate (CAGR) for revenue over the next three years, driven by an expected 12.57% CAGR in EBIT .

Institutional investors have shown continued interest in the company. Bank of New York Mellon Corp has invested an additional $1.51 million in Acme United, increasing its position . This institutional purchase highlights continued interest in the company, which operates well-established brands in the consumer, professional, and industrial markets . However, this move coincides with recent insider selling activity, where directors and officers reduced their holdings by approximately 25,722 shares over the last quarter .

What Are The Key Risks And Future Growth Drivers?

Despite the positive outlook, Acme United faces several key risks. Elevated selling, general, and administrative (SG&A) expenses at 32% of sales remain a concern . Ongoing tariff and freight costs, currency headwinds, and uneven geographic performance, particularly with Canada lagging, also pose challenges . The company is pursuing operational leverage through several initiatives, including capacity expansion for Spill Magic and regulatory certification for Med-Nap to access the hospital market .

The company is also launching smart compliance software for automated first aid replenishment, which could open new revenue streams . Core businesses are benefiting from cost reductions via Asian sourcing teams and freight consolidation . Long-term growth drivers include these capacity expansions and the integration of MyMedic into retail channels . Management expects MyMedic profitability to strengthen significantly in the fourth quarter due to seasonal demand and holiday spending .

The company's dividend payout ratio stands at 26.89%, indicating a balanced approach to shareholder returns and capital retention . Despite insider sales, insiders still hold a significant 29.50% ownership stake in the company . This substantial insider ownership aligns the interests of management and shareholders, providing a layer of confidence for investors.

Acme United's strategic focus on margin recovery and operational efficiency positions it well for future growth. The integration of MyMedic into mass retail channels and the easing of tariff pressures are expected to drive profitability in the coming quarters. Investors should monitor the company's progress in managing SG&A expenses and navigating geopolitical trade risks.